Icosapent ethyl

Icosapent ethyl is a prescription drug made of purified EPA (eicosapentaenoic acid), one of the two omega-3 fats in oily fish. It is the only omega-3 with guideline support for preventing heart attacks, because one large trial at 4 g a day cut major heart events by a quarter. That trial's placebo may have flattered it, a matching trial of an EPA+DHA mix found nothing, and the drug brings more atrial fibrillation and bleeding.

It is for people already on a statin who are at high heart risk and whose triglycerides stay raised, at 4 g a day, as a decision with your doctor. It is not a reason to take over-the-counter fish oil at high doses.

What it is

Icosapent ethyl is EPA in its ethyl-ester form, the most common pharmaceutical form of omega-3. The body has to split the ester off with a digestive enzyme before it can absorb the fat, which works better when it is taken with a fatty meal. Unlike ordinary fish oil, it contains no DHA (docosahexaenoic acid), the other long-chain omega-3. For omega-3 in general, from fish, capsules or algae, see Omega-3.

The trial that put it on the map

Over about five years, 8,179 adults with raised triglycerides, a blood fat, who were already on a statin took 4 g a day of icosapent ethyl or a placebo. The drug group had 25% fewer major cardiovascular events. That is about 4–5 fewer events for every 100 high-risk patients treated, a clinically meaningful gain on top of statin treatment.^[1]

Prescription omega-3 at 4 g a day also lowers triglycerides by 20–30%, more in people who start higher.^[2]

Why the result is disputed

A similar trial used 4 g a day of a mixed EPA+DHA product, compared it with corn oil, and found no effect on heart events.^[3] Two explanations compete, and neither is settled.

The molecule. Perhaps pure EPA works and the mix doesn't. Pooling 16 trials, purified EPA went with about 21% fewer heart deaths and EPA+DHA mixes with about 8% fewer. The gap between the two was not statistically significant, and most of the EPA trials were open-label studies from Japan without a placebo.^[4] Some lab research suggests DHA may partly offset EPA's effects, but the case that the molecule matters still rests mostly on the one big trial.

The placebo. The winning trial's dummy capsules held mineral oil. After a year, the comparison group's LDL ("bad") cholesterol had risen by about 11% and its high-sensitivity C-reactive protein, an inflammation marker, by about 22%. That may have made the drug look better by comparison. The trial's own biomarker analysts called the impact on the result uncertain.^[5] The US Food and Drug Administration (FDA) estimated that the mineral oil's effect on these markers could explain at most about 3% of the benefit.^[6] The null trial's corn oil is more biologically inert.

A second trial, without mineral oil

A 2024 Japanese trial gives a partial answer. Its control group simply got no extra treatment. In 2,506 statin-treated people with coronary disease and a low blood ratio of EPA to arachidonic acid (an omega-6 fat), 1.8 g a day of purified EPA for five years was followed by about 21% fewer heart events (9.1% against 12.6%). That is a similar size to the first trial, but the result just missed statistical significance, and patients knew which group they were in. New atrial fibrillation roughly doubled (3.1% against 1.6%).^[7] It supports the first trial without settling the question.

Who the guidelines say it is for

The 2026 US cholesterol guideline says icosapent ethyl "may be reasonable" for people on a statin who are at high heart risk (aged 50 or over, with cardiovascular disease or with diabetes plus another risk factor), whose triglycerides stay at about 1.7–5.6 mmol/L and whose LDL is below 2.6 mmol/L. The same guideline rates dietary supplements as "no benefit" for lowering cholesterol or triglycerides, and notes that non-prescription fish oil has not shown clinical benefit for high triglycerides or heart disease.^[8] The European guideline says it "should be considered" at triglycerides of 1.5–5.6 mmol/L.^[9]

The costs: atrial fibrillation and bleeding

Atrial fibrillation, an irregular heart rhythm, is the main trade-off. Pooling 7 heart trials in 81,210 patients, including this drug's trial and the null EPA+DHA trial at 4 g a day, new atrial fibrillation was about 25% more common on omega-3 than on placebo, and about 49% more common above 1 g a day.^[10] A larger analysis of 35 trials, co-funded by an omega-3 industry body, found the odds about 40% higher above 1.5 g a day in people already at high heart risk, about 1 extra case per 125 people treated.^[11] At 4 g a day, that extra atrial fibrillation is a trade worth making only where the dose has shown benefit, which means this drug in high-risk patients.

Bleeding rose with this drug and not clearly with other omega-3. In a pooled analysis of trials with over 120,000 participants, mostly older adults with or at risk of heart disease, and funded by the drug's maker, omega-3 overall did not significantly raise bleeding. High-dose purified EPA raised bleeding by about half in relative terms, about 1 extra bleed for every 166 people treated, with no clear rise in serious bleeding. Across trials, extra bleeding tracked the EPA dose rather than how many participants also took antiplatelet drugs such as aspirin; that was a trial-level comparison, not a test in individual aspirin users.^[12] Blood thinners such as warfarin or apixaban were not analysed separately. Stopping high doses about a week before planned surgery is a common precaution, but it rests on caution rather than trial evidence.

What to do

If you are 50 or over with cardiovascular disease, or with diabetes plus another risk factor, take a statin and your triglycerides stay high, ask your doctor whether icosapent ethyl fits you.
If you take a blood thinner, have atrial fibrillation or are at high risk of it, or have surgery planned, weigh the rhythm and bleeding risks with your prescriber before starting.
Don't copy the trial with shop-bought fish oil. The benefit was shown for prescription purified EPA, not for over-the-counter EPA+DHA capsules, and high doses of those bring the rhythm risk without the evidence.